SEC Form 4

Incentive Stock Option

(right to buy)⁽¹⁾

\$36.87

Explanation of Responses:

06/15/2023⁽¹⁾

1. Represents option granted by the Issuer pursuant to its 2021 Omnibus Equity Incentive Plan.

2. 25% vest on June 15, 2024 and the remainder vest quarterly (in equal amounts) over the subsequent 12 quarters.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

Γ OMB APPROVAL

OMB Number:	3235-0287								
Estimated average burden									
hours per response:	0.5								

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] Marucci Anthony S				2. Issuer Name and Ticker or Trading Symbol Celldex Therapeutics, Inc. [CLDX]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner							
(Last) C/O CEI	`	First) ERAPEUTICS,	(Middle) INC.		3. Date of Earliest Transaction (Month/Day/Year) 06/15/2023						X	below)	(give title RESIDE	Other (spec below) ENT & CEO		specify		
53 FRONTAGE ROAD, SUITE 220				4. If Amendment, Date of Original Filed (Month/Day/Year)						6. Individual or Joint/Group Filing (Check Applicable Line)								
(Street) HAMPT	'ON N	IJ	08827										X		-		orting Perso I One Repo	
(City)	Image: style (Zip) Rule 10b5-1(c) Transaction Indication Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.													to satisfy				
		Та	ble I - Nor	n-Deriva	tive S	Securitie	es A	cquired, D	Disp	oosed o	of, or Bo	enefi	cially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D				Execution Date		e, Transaction D Code (Instr. 5			4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 5)				es Fo ially (D) Following (I)		r Direct r Indirect str. 4)	7. Nature of Indirect Beneficial Ownership		
						Code	v	Amount	(A) (D)		Price	Reported Transaction(s) (Instr. 3 and 4)				(Instr. 4)		
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Ye	Code (Instr.		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exer Expiration D (Month/Day/		7. Title and Amo of Securities Underlying Derivative Secu (Instr. 3 and 4)			8. Price of Derivative Security (Instr. 5)			Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)	
				Cod	le V	(A)	(D)	Date Exercisable		xpiration	Title	or Nun	ount nber hares		(Instr. 4)	1011(5)		

06/15/2024⁽²⁾

Commo

Stock

250,000

/s/ Samuel B. Martin, attorney-

in-fact for Anthony S. Marucci ** Signature of Reporting Person

\$<mark>0</mark>

250,000

06/20/2023

Date

D

06/15/2033

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

V (A)

250,000

Α

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.